JP2006527775A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006527775A5 JP2006527775A5 JP2006517257A JP2006517257A JP2006527775A5 JP 2006527775 A5 JP2006527775 A5 JP 2006527775A5 JP 2006517257 A JP2006517257 A JP 2006517257A JP 2006517257 A JP2006517257 A JP 2006517257A JP 2006527775 A5 JP2006527775 A5 JP 2006527775A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- alkyl
- optionally
- aryl
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 66
- 125000003118 aryl group Chemical group 0.000 claims 38
- 125000000217 alkyl group Chemical group 0.000 claims 37
- 125000005843 halogen group Chemical group 0.000 claims 29
- 125000001424 substituent group Chemical group 0.000 claims 21
- 125000001589 carboacyl group Chemical group 0.000 claims 19
- 125000003545 alkoxy group Chemical group 0.000 claims 17
- 125000004093 cyano group Chemical group *C#N 0.000 claims 16
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 15
- -1 -N (R 6a ) (R 6b ) Chemical group 0.000 claims 13
- 125000003342 alkenyl group Chemical group 0.000 claims 13
- 125000000753 cycloalkyl group Chemical group 0.000 claims 13
- 125000003710 aryl alkyl group Chemical group 0.000 claims 10
- 125000000304 alkynyl group Chemical group 0.000 claims 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 9
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 102000003840 Opioid Receptors Human genes 0.000 claims 5
- 108090000137 Opioid Receptors Proteins 0.000 claims 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- 125000004423 acyloxy group Chemical group 0.000 claims 4
- 125000003435 aroyl group Chemical group 0.000 claims 4
- 125000004104 aryloxy group Chemical group 0.000 claims 4
- 210000003169 central nervous system Anatomy 0.000 claims 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 4
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims 3
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims 3
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims 3
- 229960001410 hydromorphone Drugs 0.000 claims 3
- 102000048260 kappa Opioid Receptors Human genes 0.000 claims 3
- 229960001797 methadone Drugs 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 229940005483 opioid analgesics Drugs 0.000 claims 3
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 claims 3
- 229960004739 sufentanil Drugs 0.000 claims 3
- 229960004380 tramadol Drugs 0.000 claims 3
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims 3
- 108020001588 κ-opioid receptors Proteins 0.000 claims 3
- WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 claims 2
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 claims 2
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 claims 2
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims 2
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 claims 2
- 229960001391 alfentanil Drugs 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims 2
- 229960001736 buprenorphine Drugs 0.000 claims 2
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 claims 2
- 229960001113 butorphanol Drugs 0.000 claims 2
- 229960004126 codeine Drugs 0.000 claims 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Natural products C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 229960004193 dextropropoxyphene Drugs 0.000 claims 2
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 claims 2
- 229960003461 dezocine Drugs 0.000 claims 2
- VTMVHDZWSFQSQP-VBNZEHGJSA-N dezocine Chemical compound C1CCCC[C@H]2CC3=CC=C(O)C=C3[C@]1(C)[C@H]2N VTMVHDZWSFQSQP-VBNZEHGJSA-N 0.000 claims 2
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 claims 2
- 229960000920 dihydrocodeine Drugs 0.000 claims 2
- 229960002428 fentanyl Drugs 0.000 claims 2
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 150000004677 hydrates Chemical class 0.000 claims 2
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims 2
- 229960000240 hydrocodone Drugs 0.000 claims 2
- 229960003406 levorphanol Drugs 0.000 claims 2
- 229960005181 morphine Drugs 0.000 claims 2
- 102000051367 mu Opioid Receptors Human genes 0.000 claims 2
- 229960000805 nalbuphine Drugs 0.000 claims 2
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 claims 2
- 229960002085 oxycodone Drugs 0.000 claims 2
- 229960005118 oxymorphone Drugs 0.000 claims 2
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 claims 2
- 229960005301 pentazocine Drugs 0.000 claims 2
- 229960000482 pethidine Drugs 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- ZBAFFZBKCMWUHM-UHFFFAOYSA-N propiram Chemical compound C=1C=CC=NC=1N(C(=O)CC)C(C)CN1CCCCC1 ZBAFFZBKCMWUHM-UHFFFAOYSA-N 0.000 claims 2
- 229950003779 propiram Drugs 0.000 claims 2
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 claims 2
- 108020001612 μ-opioid receptors Proteins 0.000 claims 2
- 206010010774 Constipation Diseases 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000002877 alkyl aryl group Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 230000008499 blood brain barrier function Effects 0.000 claims 1
- 210000001218 blood-brain barrier Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 claims 1
- 208000003243 intestinal obstruction Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/462,507 | 2003-06-16 | ||
| US10/462,507 US6992090B2 (en) | 2003-06-16 | 2003-06-16 | Substituted piperidine compounds and methods of their use |
| PCT/US2004/018905 WO2004112704A2 (en) | 2003-06-16 | 2004-06-15 | Substituted piperidine compounds and methods of their use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006527775A JP2006527775A (ja) | 2006-12-07 |
| JP2006527775A5 true JP2006527775A5 (https=) | 2011-12-01 |
| JP4889487B2 JP4889487B2 (ja) | 2012-03-07 |
Family
ID=33511484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006517257A Expired - Fee Related JP4889487B2 (ja) | 2003-06-16 | 2004-06-15 | 置換されたピペリジン化合物とその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US6992090B2 (https=) |
| EP (2) | EP1638565A4 (https=) |
| JP (1) | JP4889487B2 (https=) |
| CN (1) | CN1826115B (https=) |
| AU (1) | AU2004249178B2 (https=) |
| BR (1) | BRPI0411585A (https=) |
| CA (1) | CA2529524A1 (https=) |
| WO (1) | WO2004112704A2 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7381721B2 (en) | 2003-03-17 | 2008-06-03 | Adolor Corporation | Substituted piperidine compounds |
| US6992090B2 (en) * | 2003-06-16 | 2006-01-31 | Adolor Corporation | Substituted piperidine compounds and methods of their use |
| US8131026B2 (en) | 2004-04-16 | 2012-03-06 | Validity Sensors, Inc. | Method and apparatus for fingerprint image reconstruction |
| WO2006041780A1 (en) | 2004-10-04 | 2006-04-20 | Validity Sensors, Inc. | Fingerprint sensing assemblies comprising a substrate |
| MY145633A (en) | 2006-03-01 | 2012-03-15 | Theravance Inc | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists |
| US20100222345A1 (en) * | 2006-08-09 | 2010-09-02 | Caroline Jean Diaz | Novel compounds as antagonists or inverse agonists for opioid receptors |
| TWI409067B (zh) | 2007-02-28 | 2013-09-21 | Theravance Inc | ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型 |
| CA2688570A1 (en) * | 2007-05-31 | 2008-12-04 | F.P.L. Pharma Inc. | Compositions for prevention or treatment of anorexia-cachexia syndrome and uses thereof |
| JP2010536749A (ja) * | 2007-08-15 | 2010-12-02 | シェーリング コーポレイション | １１β−ヒドロキシステロイドデヒドロゲナーゼＩ型を阻害するのに有用な置換二環式ピペリジニルスルホンアミドおよびピペラジニルスルホンアミド |
| ATE502939T1 (de) | 2007-08-27 | 2011-04-15 | Theravance Inc | Disubstituierte alkyl-8-azabicycloä3.2.1üoktan- verbindungen als mu-opioid-rezeptorantagonisten |
| ES2390195T3 (es) * | 2007-08-27 | 2012-11-07 | Theravance, Inc. | Compuestos de amidoalquil-8-azabiciclo(3,2,1)octano, como antagonistas del receptor opioide mu |
| TWI423801B (zh) * | 2007-08-27 | 2014-01-21 | Theravance Inc | 作為μ類鴉片受體拮抗劑之８－氮雜雙環〔３．２．１〕辛基－２－羥基苯甲醯胺化合物 |
| EP2195313B1 (en) * | 2007-08-27 | 2014-04-02 | Theravance, Inc. | Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists |
| JP2011500686A (ja) * | 2007-10-18 | 2011-01-06 | アイコ バイオテクノロジー | オピオイドと中性アンタゴニストを用いる組合せ鎮痛剤 |
| US8748448B2 (en) | 2007-10-18 | 2014-06-10 | Aiko Biotechnology | Combination analgesic employing opioid agonist and neutral antagonist |
| JP5757864B2 (ja) | 2008-05-20 | 2015-08-05 | ニューロジェシックス， インコーポレイテッド | 水溶性アセトアミノフェン類似体 |
| EP2291084A4 (en) | 2008-05-20 | 2012-04-25 | Neurogesx Inc | CARBONATE PRODRUGS AND METHOD FOR THEIR USE |
| US20100311782A1 (en) * | 2009-06-08 | 2010-12-09 | Adolor Corporation | Substituted piperidinylpropanoic acid compounds and methods of their use |
| WO2011161646A2 (en) | 2010-06-25 | 2011-12-29 | Ranbaxy Laboratories Limited | Process for the preparation of alvimopan or its pharmaceutically acceptable salt or solvate thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4191771A (en) * | 1974-09-06 | 1980-03-04 | Eli Lilly And Company | Analgesic method using 1,3,4-trisubstituted-4-arylpiperidines |
| US4115400A (en) | 1976-05-27 | 1978-09-19 | Eli Lilly And Company | 1-Azoniabicyclo[3.1.0]hexanes |
| US4176186A (en) | 1978-07-28 | 1979-11-27 | Boehringer Ingelheim Gmbh | Quaternary derivatives of noroxymorphone which relieve intestinal immobility |
| NZ191763A (en) * | 1978-10-13 | 1984-05-31 | Hoffmann La Roche | 7-beta-phenyl-quinolidines, intermediates and pharmaceutical compositions |
| US4931558A (en) * | 1983-09-21 | 1990-06-05 | Eli Lilly And Company | Processes for preparing intermediates of picenadol |
| US4891379A (en) | 1987-04-16 | 1990-01-02 | Kabushiki Kaisha Kobe Seikosho | Piperidine opioid antagonists |
| GB8803076D0 (en) | 1988-02-10 | 1988-03-09 | Erba Carlo Spa | 3'-deamino-4'-deoxy-4'-amino anthracyclines |
| ZA922180B (en) * | 1991-03-29 | 1993-09-27 | Lilly Co Eli | Piperidine derivatives |
| US5250542A (en) | 1991-03-29 | 1993-10-05 | Eli Lilly And Company | Peripherally selective piperidine carboxylate opioid antagonists |
| US5159081A (en) | 1991-03-29 | 1992-10-27 | Eli Lilly And Company | Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists |
| US5270328A (en) | 1991-03-29 | 1993-12-14 | Eli Lilly And Company | Peripherally selective piperidine opioid antagonists |
| US5434171A (en) * | 1993-12-08 | 1995-07-18 | Eli Lilly And Company | Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates |
| US5972954A (en) | 1997-11-03 | 1999-10-26 | Arch Development Corporation | Use of methylnaltrexone and related compounds |
| EP1512683B1 (en) | 1998-03-10 | 2011-08-31 | Research Triangle Institute | Novel opiate compounds, methods of making and methods of use |
| US6900228B1 (en) * | 1998-03-10 | 2005-05-31 | Research Triangle Institute | Opiate compounds, methods of making and methods of use |
| GB9912411D0 (en) * | 1999-05-28 | 1999-07-28 | Pfizer Ltd | Compounds useful in therapy |
| US6451806B2 (en) * | 1999-09-29 | 2002-09-17 | Adolor Corporation | Methods and compositions involving opioids and antagonists thereof |
| WO2001041705A2 (en) * | 1999-11-29 | 2001-06-14 | Adolor Corporation | Novel methods for the treatment and prevention of dizziness and pruritus |
| MXPA02005336A (es) * | 1999-11-29 | 2003-01-28 | Adolor Corp | Metodos novedosos para el tratamiento y prevencion del ileo. |
| ES2278647T3 (es) * | 1999-11-29 | 2007-08-16 | Adolor Corporation | Nuevos procedimientos y composiciones que comprenden opioides y antagonistas de opioides. |
| US20030100562A1 (en) * | 1999-11-30 | 2003-05-29 | Yudu Cheng | Diketopiperazine derivatives to inhibit thrombin |
| JPWO2002030896A1 (ja) | 2000-10-12 | 2004-02-19 | エスエス製薬株式会社 | ２，２−ジフェニルブタンアミド誘導体及びこれを含有する医薬 |
| JP4340437B2 (ja) | 2000-10-31 | 2009-10-07 | レンセラール ポリテクニック インスティチュート | ８−カルボキサミド−２，６−メタノ−３−ベンズアゾシン |
| US6974824B2 (en) | 2001-01-08 | 2005-12-13 | Research Triangle Institute | Kappa opioid receptor ligands |
| US6794510B2 (en) * | 2002-08-08 | 2004-09-21 | Adolor Corporation | Processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto |
| US7381721B2 (en) * | 2003-03-17 | 2008-06-03 | Adolor Corporation | Substituted piperidine compounds |
| US20040204453A1 (en) * | 2003-04-14 | 2004-10-14 | Pfizer Inc | 4-Phenyl-piperidine compounds and their use as modulators of opioid receptors |
| US6992090B2 (en) * | 2003-06-16 | 2006-01-31 | Adolor Corporation | Substituted piperidine compounds and methods of their use |
-
2003
- 2003-06-16 US US10/462,507 patent/US6992090B2/en not_active Expired - Fee Related
-
2004
- 2004-06-15 AU AU2004249178A patent/AU2004249178B2/en not_active Ceased
- 2004-06-15 EP EP04755219A patent/EP1638565A4/en not_active Withdrawn
- 2004-06-15 CA CA002529524A patent/CA2529524A1/en not_active Abandoned
- 2004-06-15 CN CN2004800194266A patent/CN1826115B/zh not_active Expired - Fee Related
- 2004-06-15 WO PCT/US2004/018905 patent/WO2004112704A2/en not_active Ceased
- 2004-06-15 EP EP11166283A patent/EP2394992A3/en not_active Withdrawn
- 2004-06-15 BR BRPI0411585-6A patent/BRPI0411585A/pt not_active IP Right Cessation
- 2004-06-15 JP JP2006517257A patent/JP4889487B2/ja not_active Expired - Fee Related
-
2005
- 2005-09-01 US US11/217,528 patent/US7820827B2/en not_active Expired - Fee Related
-
2010
- 2010-10-05 US US12/897,824 patent/US8288546B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006527775A5 (https=) | ||
| JP2003528819A5 (https=) | ||
| US12582647B2 (en) | Systems and methods for treating an opioid-induced adverse pharmacodynamic response | |
| JP2005530798A5 (https=) | ||
| ES2729679T3 (es) | Derivados de morfinano para el tratamiento de la sobredosis de fármacos | |
| RU2009125597A (ru) | Пролекарства и способы их получения и применения | |
| RU2005113996A (ru) | Способы лечения боли введением антагониста фактора роста нервов и опиоидного анальгетика, и содержащие их композиции | |
| JP2002506047A (ja) | Ｎｍｄａレセプター拮抗薬及び麻酔性鎮痛薬を含む鎮痛組成物。 | |
| WO2020055725A4 (en) | Dopamine d3 receptor selective antagonists/partial agonists and uses thereof | |
| JP2003517476A5 (https=) | ||
| JP2008534613A5 (https=) | ||
| US10226457B2 (en) | Systems and methods for treating an opioid-induced adverse pharmacodynamic response | |
| JP2005500373A5 (https=) | ||
| HUP0401013A2 (hu) | Hatóanyag-kombináció nikotinfüggőség gyógyszeres kezelésére és ezt tartalmazó gyógyszerkészítmény | |
| JP2011513278A5 (https=) | ||
| JP2006516267A5 (https=) | ||
| JP2002526409A5 (https=) |